论文部分内容阅读
目的:探讨aAd-p53注射液靶向灌注治疗癌性胸腹水的临床疗效和安全性。方法:选择2012年5月-2014年2月在我院接受治疗的癌性胸腹水患者80例,根据治疗方法的不同,将患者随机分为研究组和对照组,每组40例。研究组患者采用腔内灌注rAd-p53治疗,对照组患者采用表阿霉素灌注治疗,观察并比较两组患者的治疗总有效率、不良反应的发生率及KPS功能评分的变化情况。结果:所有患者均顺利完成灌注治疗,病情获得好转,生存质量得到改善。研究组和对照组的治疗总有效率分别为70%、67.5%,两组比较无显著性差异(P>0.05)。两组治疗后KPS评分均显著高于治疗前,且研究组高于对照组,差异具有统计学意义(P<0.05)。研究组和对照组不良反应的发生率分别为20%和25%,研究组低于对照组,但两组差异并无统计学意义(P>0.05)。结论:rAd-p53注射液靶向灌注治疗是一种治疗癌性胸腹水安全有效的方法,值得临床推广。
Objective: To investigate the clinical efficacy and safety of targeted aAd-p53 injection in the treatment of malignant ascites and pleural effusion. Methods: Eighty patients with malignant ascites and hydrothorax were treated in our hospital from May 2012 to February 2014. According to the different treatment methods, the patients were randomly divided into study group and control group, 40 cases in each group. Patients in the study group were treated with intraluminal infusion of rAd-p53, and patients in the control group were treated with epirubicin infusion. The total effective rate of treatment, the incidence of adverse reactions and changes in KPS function scores were observed and compared between the two groups. Results: All patients successfully completed perfusion treatment, the condition was improved, the quality of life improved. The total effective rate of study group and control group was 70% and 67.5% respectively, there was no significant difference between the two groups (P> 0.05). KPS scores of both groups were significantly higher than those before treatment, and the study group was higher than the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in study group and control group was 20% and 25%, respectively. The study group was lower than the control group, but there was no significant difference between the two groups (P> 0.05). Conclusion: Targeting perfusion of rAd-p53 injection is a safe and effective method for the treatment of malignant pleural effusion and is worthy of clinical promotion.